$COSMJun 15, 2026, 4:52 PMAI processed
COSM launches 4 U.S. 18-Series nutraceuticals targeting >$22.7M revenue and ~$17M gross profit
AI Summary
Cosmos Health (NASDAQ: COSM) gave a U.S. commercial update for its '18 Series' nutraceutical platform, announcing four products with company-projected annualized U.S. revenue of over $22.7M and implied gross profit of roughly $17.0M (using ~75% gross margin). The platform is early-stage (five products launched, one without a projection), selling direct-to-consumer with reported early demand and planned retail expansion; the figures are forward-looking company projections, not audited results.
Positives
- Company projects >$22.7M in annualized U.S. revenue across four 18 Series products
- Implied gross profit of ~ $17.0M based on the company’s ~75% gross-margin assumption
- Management reports encouraging early demand and plans to expand from DTC into retail
Negatives
- Projected revenue and gross profit are forward-looking company targets, not verified sales
- Platform remains early-stage (5 products launched; Oliv18 has no disclosed projection)
- Projections assume a ~75% gross margin which may not be realized in practice